Trial ID or NCT#

NCT02693080

Status

RECRUITING

Purpose

This study assesses computed tomography (CT) perfusion imaging in predicting treatment response in patients with non-small cell lung cancer or tumors that have spread from the primary site (place where it started) to the lungs (metastases) treated with stereotactic ablative radiation therapy. CT perfusion imaging is a special type of CT that uses an injected dye in order to see how blood flow through tissues, including lung tissue. CT perfusion imaging of the lungs may help doctors learn whether perfusion characteristics of lung tumors may be predictive of response to treatment and whether lung perfusion characteristics can be used to follow response to treatment.

Official Title

A Pilot Study of Perfusion CT for Lung Tumors Treated With Stereotactic Ablative Radiation Therapy (SABR)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Maximilian Diehn, MD, PhD
Radiation oncologist
Associate Professor of Radiation Oncology (Radiation Therapy)
Billy W. Loo, Jr., MD, PhD, DABR
Radiation oncologist, Thoracic specialist
Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Samantha Wong
(650) 498-8495